Holen Sie sich die Stockscreener-App
0.00
100.00%
-7.15
Handel nachbörslich:
7.14
7.14
+
Schlusskurs vom Vortag:
$7.15
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$377.22M
Einnahmen:
$58.20M
Nettoeinkommen (Verlust:
$-44.77M
KGV:
0.00
EPS:
-1.69
Netto-Cashflow:
$-37.54M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$7.19
G 1 Therapeutics Inc Stock (GTHX) Company Profile
Firmenname
G 1 Therapeutics Inc
Sektor
Branche
Telefon
919-213-9835
Adresse
700 PARK OFFICES DRIVE, RESEARCH TRIANGLE PARK, NC
Vergleichen Sie GTHX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GTHX
G 1 Therapeutics Inc
|
0.00 | 377.22M | 58.20M | -44.77M | -37.54M | -0.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
G 1 Therapeutics Inc Stock (GTHX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-01-03 | Bestätigt | Needham | Buy |
| 2021-11-04 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-09-30 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-11-17 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-26 | Eingeleitet | ROTH Capital | Buy |
| 2020-01-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-02-07 | Eingeleitet | B. Riley FBR | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-20 | Eingeleitet | Raymond James | Strong Buy |
| 2018-11-08 | Bestätigt | Needham | Buy |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-05-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-05-18 | Bestätigt | Needham | Buy |
Alle ansehen
G 1 Therapeutics Inc Aktie (GTHX) Neueste Nachrichten
Layoff Tracker: Bavarian, BenevolentAI, Chroma Medicine and Nvelop Therapeutics Cut Staff - BioSpace
Indapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple Myeloma Program - Business Wire
Earnings Flash (GTHX) G1 THERAPEUTICS Posts Q3 Revenue $12.3M, vs. Street Est of $14.2M - Marketscreener.com
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer - Marketscreener.com
G1 Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $12.9M, vs. Street Est of $11.4M - Marketscreener.com
Insider Sell: G1 Therapeutics - Marketscreener.com
G1 Therapeutics, Inc. Announces Executive Changes - Marketscreener.com
ScaleReady Announces a G-Rex® Grant has been awarded to Luminary Therapeutics - Yahoo Finance
Needham Adjusts Price Target on G1 Therapeutics to $32 From $42, Reiterates Buy Rating - Marketscreener.com
HC Wainwright Adjusts G1 Therapeutics Price Target to $57 From $67, Maintains Buy Rating - Marketscreener.com
G1 Therapeutics Says Study Confirms Myelosuppression Risk In Patients Getting Chemotherapy for Lung Cancer - Marketscreener.com
G1 Therapeutics Says Phase 2 Trial Shows Objective Response Rate of 40% in Patients With Bladder Cancer - Marketscreener.com
Needham Adjusts Price Target on G1 Therapeutics to $31 From $32, Maintains Buy Rating - Marketscreener.com
G1 Therapeutics : to Provide Third Quarter 2020 Corporate and Financial Update on November 4, 2020 - Marketscreener.com
G1 Therapeutics : to Provide Second Quarter 2020 Corporate and Financial Update on August 5, 2020 - Marketscreener.com
G1 Therapeutics to End Colorectal Cancer Trial of Drug Therapy; Shares Plunge - Marketscreener.com
G1 Therapeutics Says Trilaciclib Shows Potential for Improved Clinical Outcome in Phase 2 Breast Cancer Trial - Marketscreener.com
G-Protein Coupled Receptors Market Growth Analysis, Trends, Share, Market Size And Forecast To 2033 - WhaTech
46,234 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Acquired by Federated Hermes Inc. - Defense World
Global study predicts sharp rise in cancer rates among men by 2050 - Benefits and Pensions Monitor
Edgewise Therapeutics (EWTX) Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy - StreetInsider.com
Edgewise Therapeutics, Inc Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy - Marketscreener.com
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) - Business Wire
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer - GlobeNewswire
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer - Benzinga
why G1 Therapeutics Inc [GTHX] is a Good Choice for Investors After New Price Target of $7.15 - The DBT News
G1 Therapeutics Inc [GTHX] Insider Perry Andrew sells 1,337 Shares - Knox Daily
G1 Therapeutics Inc: Navigating a Turbulent Year, Up -0.70% from 52-Week Low - The InvestChronicle
Acadian Asset Management LLC Increases Stake in G1 Therapeutics, Inc. (NASDAQ:GTHX) - MarketBeat
Insider Selling: Perry Andrew, G1 Therapeutics Inc [GTHX] Chief Commercial Officer divested 1,337 shares - Knox Daily
Recent Insider Activity Could Benefit G1 Therapeutics Inc (GTHX) - Knox Daily
Exploring High Growth Tech Stocks in the United States for September 2024 - Simply Wall St
Pharmacosmos moves forward with G1 Therapeutics buyout - Investing.com India
GTHXG1 Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period - GlobeNewswire
Keeping an Eye on G1 Therapeutics Inc (GTHX) After Insider Trading Activity - Knox Daily
Panagora Asset Management Inc. Buys New Shares in G1 Therapeutics, Inc. (NASDAQ:GTHX) - MarketBeat
A company insider recently sold 1,337 shares of G1 Therapeutics Inc [GTHX]. Should You Sale? - Knox Daily
The Significance of Moving Averages in G1 Therapeutics Inc Inc. (GTHX) Price Performance - The InvestChronicle
G1 Therapeutics Inc (GTHX) gets rating Upgrade from JP Morgan - Knox Daily
Stock Market Recap: G1 Therapeutics Inc (GTHX) Concludes at 7.12, a 0.28 Surge/Decline - The Dwinnex
It is Poised to be a Bull Market for G1 Therapeutics Inc (GTHX) - SETE News
G1 Therapeutics Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - The InvestChronicle
It would be worthwhile to take a closer look at G1 Therapeutics Inc (GTHX) - US Post News
Monopar Receives Clearance to Proceed with Phase 1 - GlobeNewswire
Stock Market Recap: G1 Therapeutics Inc (GTHX) Concludes at 7.09, a -0.28 Surge/Decline - The Dwinnex
Finansavisen - Finansavisen
The Potential Rise in the Price of G1 Therapeutics Inc (GTHX) following insiders activity - Knox Daily
A look into G1 Therapeutics Inc (GTHX)’s deeper side - SETE News
FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose - Yahoo Finance
Finanzdaten der G 1 Therapeutics Inc-Aktie (GTHX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):